ILution travoprost is under clinical development by Glaukos and currently in Phase II for Ocular Hypertension. According to GlobalData, Phase II drugs for Ocular Hypertension have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ILution travoprost’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ILution travoprost overview
Travoprost is under development for the treatment of open-angle glaucoma and ocular hypertension. The drug candidate is administered as an ophthalmic topical cream. It acts by targeting prostaglandin F2-alpha receptor and is being developed based on iLution platform.
Glaukos overview
Glaukos is an ophthalmic medical device company that researches and develops micro technologies to improve glaucoma therapy. The company develops injectable micro-scale therapies to address the complete range of glaucoma disease states and progression. It provides products such as micro stent devices to treat glaucoma such as iStent trabecular micro-bypass stent for the treatment of mild- to moderate-open-angle glaucoma. Glaukos’ iStent is used in conjunction with cataract surgery. Glauko’s iStent improves outflow by creating a patent bypass between the anterior chamber and Schlemm’s canal. The company markets its products through a network of distributors in Germany, Canada, the UK, Australia, Brazil and Japan, among others. Glaukos is headquartered in San Clemente, California, the US.
For a complete picture of ILution travoprost’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
